Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ADJUVANT THERAPY OF STAGE IIIB MELANOMA WITH INTERFERON ALFA-2B - CLINICAL AND IMMUNOLOGICAL RELEVANCE
Autore:
DOVEIL GC; FIERRO MT; NOVELLI M; APPINO A; BERTERO M; QUAGLINO P; BERNENGO MG;
Indirizzi:
UNIV TURIN,DERMATOL CLIN,VIA CHERASCO 23 I-10126 TURIN ITALY UNIV TURIN,DERMATOL CLIN 1 I-10126 TURIN ITALY
Titolo Testata:
Dermatology
fascicolo: 3, volume: 191, anno: 1995,
pagine: 234 - 239
SICI:
1018-8665(1995)191:3<234:ATOSIM>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; LYMPH-NODE METASTASES; PHASE-II; SKIN MELANOMA; TRIALS; LEVAMISOLE; PROGNOSIS;
Keywords:
METASTATIC MELANOMA DRUG THERAPY; STAGE IIIB MELANOMA; ADJUVANT IMMUNOTHERAPY; INTERFERON ALFA-2B; IMMUNOPHENOTYPING;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
G.C. Doveil et al., "ADJUVANT THERAPY OF STAGE IIIB MELANOMA WITH INTERFERON ALFA-2B - CLINICAL AND IMMUNOLOGICAL RELEVANCE", Dermatology, 191(3), 1995, pp. 234-239

Abstract

Background: The poor prognosis of stage IIIb melanoma (5-year survival: 36%) shows the need for effective adjuvant therapy to prolong disease-free survival. Objective: The feasibility and efficacy of interferon alfa-2b (IFN-alpha) therapy in stage mb melanoma patients was investigated. Methods: alpha-IFN was given at a dose of 3 MU i.m. three times a week to 50 patients. Clinical and immunological controls were carried out. Results: The median follow-up was 43 months (range 5-84). Median survival was 43 months and median disease-free survival 39 months. Overall 5-year survival (62%) was higher than that reported in the literature to date. A significant increase of circulating CD56+ and DR+ lymphocytes after therapy was more evident in disease-free patients than in those with progressing disease. Conclusion: Adjuvant IFN-alpha therapy in stage IIIb melanoma patients is well tolerated and seems to increase survival. However, multicenter randomized trials are needed to confirm these preliminary findings.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 09:37:52